Does BPC-157 Cause Cancer? What the Data Says

Search BPC-157 and cancer and you will meet two confident answers. One says the peptide is a tumor hazard because it grows new blood vessels. The other says laboratory work has already settled the question in its favor. Both run ahead of the data. As of July 2026 we could find no study, in any species, that set out to measure whether BPC-157 causes cancer: no rodent bioassay, no human follow-up, nothing in either direction. What exists instead is a mechanism that makes people nervous and a literature too thin to answer them. Those are separate problems, and they are worth keeping separate. Our BPC-157 data sheet covers the compound generally; this page is about the cancer question only.^[3]

Where the cancer question comes from

The worry was not invented on forums. It comes from the peptide's own proposed mechanism. BPC-157 is described in the laboratory literature as pro-angiogenic, meaning it encourages the growth of new blood vessels, and the groups studying it have reported rises in vascular endothelial growth factor, or VEGF, alongside activation of endothelial nitric oxide synthase. A 2015 rat study of alkali burns reported faster wound closure together with greater vessel formation in cell culture. Its authors present that as the point of the compound: new vessels carry blood into damaged tissue, and damaged tissue mends better with a blood supply. Solid tumors need a blood supply for the same reason. That observation, formalized by Judah Folkman in the 1970s, is why an entire class of cancer drugs works by blocking angiogenesis rather than by attacking cancer cells directly. So a compound sold on its ability to grow vessels sits, in theory, on the wrong side of that logic. In 2025 a Polish research team writing in the journal Pharmaceuticals put exactly this into print. Tumor promotion appeared on their list of plausible hazards for a pro-angiogenic peptide with no long-term safety data behind it.^{[1, 5]}

What the theory does and does not say

A theoretical hazard is a reason to run a study, not a result. Angiogenesis in a healing tendon and angiogenesis around a tumor are the same process pointed at different tissue, and nothing published shows which one BPC-157 would favor in a person who already carries undetected cancer cells. The mechanism tells you where to look. It does not tell you what you would find. The peptide's principal defenders make the mirror-image error. In a 2025 comment answering that review, the Zagreb pharmacology group that discovered BPC-157 and is listed as first or senior author on more than 80 percent of the records for it argued that the compound modulates angiogenesis rather than simply driving it, and described what they called prominent anti-tumor potential in vivo and in vitro. Read as a statement about cancer risk in humans, that is a far larger claim than the underlying work supports.^{[2, 3]}

What has actually been observed

The Polish team's reply, published later in 2025, is the most useful document in the exchange, because it states plainly what is missing on both sides. It notes that no published in vivo data show BPC-157 slowing tumor progression, reducing tumor volume, or suppressing metastasis, and that the single unreplicated cell-line experiment offered as anti-tumor evidence cannot carry that weight. It also points out that the paper most often cited for an anti-cancer effect is about cachexia, the wasting syndrome that accompanies advanced cancer, rather than about tumor growth at all. We read that paper. It is a 2018 review proposing BPC-157 as a candidate worth testing in cachexia, and it summarizes possible mechanisms for that. It is not a study in which tumors got smaller. So the ledger is empty on both sides: no in vivo evidence that BPC-157 promotes tumors, and no in vivo evidence that it holds them back. Anyone who tells you the cancer question is settled is describing a study that does not exist.^{[3, 6]}

The human record is one trial, and it never reported

Public trial registries carry a single BPC-157 safety study in people that we could verify: NCT02637284, a Phase 1 pilot in healthy volunteers sponsored by PharmaCotherapia and planned at a hospital in Tijuana. It listed 42 volunteers and an oral tablet form of the peptide. The record has not been updated since December 2015, its registry status is unknown, and no results were ever posted. Even had it finished and reported, a three-week safety study in healthy young adults could not have detected a cancer signal. Cancers take years to surface, and 42 people is far too few to count them. That is the entire human safety base for a compound sold worldwide. How to read a peptide study is a useful skill here, mostly because it shows how quickly the BPC-157 shelf empties.^[7]

Why the evidence base itself is the problem

The reason nobody can answer the cancer question is structural. In its reply the Polish team reports that more than 80 percent of PubMed and Google Scholar records for BPC-157 list the same two researchers as first or senior author, and that independent laboratories have contributed only a handful of short in vitro or rodent studies. It also notes that experiments overwhelmingly use one exposure level, so there is no dose-response curve and no way to know whether effects grow, plateau, or turn harmful at higher exposures. A 2022 pharmacokinetic study in rats and beagle dogs, the first of its kind, found an elimination half-life under 30 minutes. None of that is proof of danger. It is an absence of the information that would let anyone rule danger in or out. A cancer signal is exactly the kind of slow, uncommon outcome that only long studies in large groups can detect, and that work has not been done.^{[3, 4]}

What the regulators have said

The FDA has not approved BPC-157 for any use. It appears on the agency's list of bulk drug substances that may present significant safety risks in compounding, where the entry states that compounded drugs containing BPC-157 may pose a risk for immunogenicity for certain routes, may carry complexities around peptide-related impurities and characterization of the active ingredient, and that no, or only limited, safety-related information has been identified. Cancer is not mentioned in that entry at all. The concerns named there are immune reaction and product quality. On 23 July 2026 the agency's Pharmacy Compounding Advisory Committee took up BPC-157 among several peptides under discussion for the 503A bulks list. A committee agenda is not a verdict, and the meeting notice makes no finding about cancer either way. In sport the answer is unambiguous. The WADA 2026 Prohibited List names BPC-157 by name in section S0, the non-approved substances class, which is prohibited at all times, in and out of competition. This is worth flagging because the 2025 review discussed above stated that BPC-157 was not then listed by WADA. The 2026 list names it explicitly, so that statement is out of date, and so is any page still repeating it.^{[1, 8, 9, 10]}

What this means if you are weighing it up

Nobody can tell you your personal risk, because the study that would inform it has not been run. What can be said is narrower, and still worth something. The theoretical concern is sharpest for people who may already carry cancer cells they do not know about, since that is the only scenario in which a pro-angiogenic compound has something to act on. That group includes anyone with a personal history of cancer, anyone in remission, and anyone with a strong family history. Nothing in the literature puts a number on that risk. Nothing in the literature rules it out either. Gray-market supply adds a separate problem with nothing to do with angiogenesis. Vials sold for laboratory research use only are not made to pharmaceutical manufacturing standards, and purity, endotoxin load, and label accuracy all go unverified. Gray-market peptides covers that in detail, and common peptide side effects covers the reactions people actually report. If you are carrying a cancer history, or you simply want this weighed against your own record, that is a conversation for a clinician who can see your history. A page cannot substitute for it, and neither can a forum thread.

References & sources

1. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. The review that raised tumorigenesis among the plausible hazards of a pro-angiogenic peptide, and that stated BPC-157 was not then named on the WADA list. PMID 40005999.
2. Sikiric P, Seiwerth S, Skrtic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Jozwiak et al. Pharmaceuticals (Basel). 2025;18(10):1450. The Zagreb group's defence, describing prominent anti-tumor potential in vivo and in vitro. PMID 41155565.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. Pharmaceuticals (Basel). 2025;18(10). States that no published in vivo data show BPC 157 inhibiting tumor progression, reducing tumor volume or suppressing metastasis; that over 80 percent of BPC 157 records list the same group as first or senior author; and that experiments routinely use a single exposure level. PMID 41155566.
4. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. Reports an elimination half-life of prototype BPC157 under 30 minutes in rats and beagle dogs, and describes itself as the first pharmacokinetic analysis of the compound. PMID 36588717.
5. Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. Rat alkali-burn model reporting faster wound closure with topical BPC-157 and increased angiogenesis in cell culture. PMID 25995620.
6. Kang EA, Han YM, An JM, et al. BPC157 as Potential Agent Rescuing from Cancer Cachexia. Curr Pharm Des. 2018;24(18):1947-1956. A review proposing BPC157 as a candidate for cancer cachexia; it is not a tumor-growth study. PMID 29898649.
7. ClinicalTrials.gov NCT02637284. PharmaCotherapia d.o.o. Phase 1 pilot study in healthy volunteers of PCO-02, whose active ingredient is BPC-157, given as an oral tablet at a single centre in Tijuana. Listed enrolment 42; record last updated December 2015; overall status unknown; no results posted.
8. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of 22 April 2026. The BPC-157 entry cites possible immunogenicity risk for certain routes, complexities around peptide-related impurities and active ingredient characterization, and no, or only limited, safety-related information for the proposed routes. Cancer is not named in the entry.
9. World Anti-Doping Agency. 2026 Prohibited List, in force 1 January 2026. Section S0, non-approved substances, names BPC-157 explicitly; the whole S0 class is prohibited at all times, in and out of competition.
10. US Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. Agenda page, content current as of 22 July 2026, lists BPC-157-related bulk drug substances among those under discussion for possible inclusion on the 503A Bulks List.